Advertisement

Privately held BioCardia touts successful results and a strong safety profile for its Helical Infusion Catheter System in delivering stem cells for treatment of heart failure.

BioCardia touts positive outcomes for Helical stem cell therapy system

California-based BioCardia Inc. announced this week positive findings from a clinical trial of its Helical Infusion Catheter System for injecting stem cells into the heart in treatment of chronic ischemic cardiomyopathy.

In a clinical study of 65 ICM patients, researchers used the Helical Infusion system to inject both autologous culture-expanded mesenchymal cells (MSCs) and autologous minimally-processed whole bone marrow mononuclear cells (BMCs), reporting success in meeting endpoints for both therapies with no treatment-emergent serious adverse events (TE-SAEs) reported at 30 days.

Advertisement
Advertisement